In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim (original) (raw)

Clinical trials in multiple sclerosis: milestones

Therapeutic advances in neurological disorders, 2018

Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts

Clarence Liu

Journal of Neurology Neurosurgery and Psychiatry, 2000

View PDFchevron_right

Impact of trial design and patient heterogeneity on the identification of clinically effective therapies for progressive MS

Caitlyn Fisher

Multiple Sclerosis Journal, 2018

View PDFchevron_right

Efficacy of Disease-Modifying Therapies in Relapsing Remitting Multiple Sclerosis: A Systematic Comparison

Ahmad AL-Sabbagh

European Neurology, 2008

View PDFchevron_right

Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression

Sebastian Straube

Multiple Sclerosis Journal, 2013

View PDFchevron_right

Redefining Acute Relapses in Multiple Sclerosis: Implications for Phase 3 Clinical Trials and Treatment Algorithms

Jagannadha Avasarala

Innovations in Clinical Neuroscience, 2017

View PDFchevron_right

Eva Havrdova

European Journal of Neurology, 2006

View PDFchevron_right

Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis

Davorka Tomic

Multiple Sclerosis Journal

View PDFchevron_right

The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

Nikolaos Grigoriadis

PloS one, 2015

View PDFchevron_right

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis

Eugenio Pucci, Maria Di Ioia

Neuropsychiatric Disease and Treatment, 2013

View PDFchevron_right

Treatment trials in progressive MS—current challenges and future directions

Gary Cutter

Nature Reviews Neurology, 2013

View PDFchevron_right

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review

Eva Havrdova

Autoimmunity reviews, 2017

View PDFchevron_right

Contrasting natural history and therapy- induced effects on disability outcomes: a systematic review of randomized, placebo controlled trials in relapsing multiple sclerosis

laura iulia

View PDFchevron_right

Clinical trial design for progressive MS trials

Gary Cutter

Multiple sclerosis (Houndmills, Basingstoke, England), 2017

View PDFchevron_right

Measuring Treatment Response in Progressive Multiple Sclerosis—Considerations for Adapting to an Era of Multiple Treatment Options

Nik Krajnc

Biomolecules, 2021

View PDFchevron_right

Relapsing–Remitting Multiple Sclerosis: Patterns of Response to Disease-Modifying Therapies and Associated Factors: A National Survey

Maria Sá, livia sousa

Neurology and Therapy, 2014

View PDFchevron_right

Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response

Arianna Merlini

Acta neurologica Scandinavica, 2018

View PDFchevron_right

Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol

Thomas Love

Contemporary Clinical Trials, 2020

View PDFchevron_right

Evolving landscapes in multiple sclerosis research: adaptive designs and novel endpoints

Manolo Beelke

Multiple Sclerosis and Demyelinating Disorders, 2016

View PDFchevron_right

Disability Progression in a Clinical Trial of Relapsing-Remitting Multiple Sclerosis

Gary Cutter

Archives of Neurology, 2010

View PDFchevron_right

Optimizing treatment success in multiple sclerosis

Filipe Palavra

Journal of Neurology, 2015

View PDFchevron_right

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials

Ludwig Kappos

JAMA Neurology

View PDFchevron_right

Number Needed to Treat in Multiple Sclerosis Clinical Trials

Karl Peace

Neurology and Therapy, 2017

View PDFchevron_right

The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations

Gabriel Pardo

Journal of neurology, 2017

View PDFchevron_right

Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis

Sayeedul Hasan Arif

Cureus

View PDFchevron_right

Summary measure” statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis

Clarence Liu

Journal of Neurology Neurosurgery and Psychiatry, 1999

View PDFchevron_right

Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients

Michele Mass

Multiple Sclerosis, 2005

View PDFchevron_right

Smoke and mirrors: Limited value of relative risk reductions for assessing the benefits of disease-modifying therapies for multiple sclerosis

Magd Zakaria

Multiple sclerosis and related disorders, 2015

View PDFchevron_right

No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis

Davorka Tomic

Advances in therapy, 2014

View PDFchevron_right

Emerging Approaches for Validating and Managing Multiple Sclerosis Relapse

Ali Mirza

Frontiers in neurology, 2017

View PDFchevron_right

Treatments for relapsing–remitting multiple sclerosis: summarising current information by network meta-analysis

F. Del Santo, Valeria Fadda, Andrea Messori

European Journal of Clinical Pharmacology, 2012

View PDFchevron_right

In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim (original) (raw)

Related papers